inhibitor productsSearch results for: inhibitor
#36944564 
2023/03/19
To Up
Increased risk of cutaneous immune-related adverse events in patients treated with talimogene laherparepvec and immune checkpoint inhibitors: A multi-hospital cohort study.
Previous studies have shown that combining immune checkpoint inhibitors (ICIs) with talimogene laherparepvec (TVEC) may improve antitumor responses. However, the risk of developing cutaneous immune-related adverse events (cirAEs) in patients treated with ICI and TVEC has not been studied.Bonnie W Leung, Guihong Wan, Nga Nguyen, Hannah Rashdan, Shijia Zhang, Wenxin Chen, Sonia Cohen, Genevieve M Boland, Ryan J Sullivan, Riley M Fadden, Howard L Kaufman, Shawn G Kwatra, Nicole R LeBoeuf, Yevgeniy R Semenov